ERAS

$10.03-0.62 (-5.82%)

Pre-Market$10.15+0.12 (+1.20%)· Last close May 1

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO